Agios Pharmaceuticals’ tebapivat gains FDA orphan drug designation

Tebapivat is intended for the treatment of myelodysplastic syndromes.

Vishnu Priyan September 12 2024

Agios Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to tebapivat (AG-946) to treat myelodysplastic syndromes (MDS).

The development comes after the company completed a Phase IIa trial of tebapivat in lower-risk MDS in 2023 and is now initiating a Phase IIb study of the asset for the same indication.

The FDA's Office of Orphan Drug Products awards ODD to aid the development of treatments for rare diseases affecting fewer than 200,000 people in the US.

The designation offers several benefits to Agios, including tax credits, FDA fee exemptions and the potential for seven years of market exclusivity post-approval.

Agios Pharmaceuticals research and development chief medical officer and head Sarah Gheuens stated: “Receiving orphan drug designation for tebapivat in MDS underscores the importance of bringing new oral treatment options to patients suffering from this rare disease.

“We aim to deliver the first oral therapy that addresses anaemia due to ineffective erythropoiesis in lower-risk MDS, which affects approximately 75,000 to 80,000 patients in France, Germany, Italy, Spain, the UK and the US, and accounts for approximately 70% of MDS cases.”

Agios focuses on developing groundbreaking therapies for patients with rare diseases.

Its lead asset is mitapivat, a PK [pyruvate kinase] activator. This asset previously received ODD for PK deficiency, thalassaemia and sickle cell disease.

In the US, Agios markets a first-in-class PK activator for adults with PK deficiency, offering a novel disease-modifying therapy for this rare and chronic haemolytic anaemia.

Agios' clinical pipeline also includes treatments for alpha and beta-thalassemia, sickle cell disease, paediatric PK deficiency, MDS-associated anaemia, and phenylketonuria.

Agios is developing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera.

In May 2024, Agios agreed to sell its stake in vorasidenib to Royalty Pharma for $905m.

The company, which owns the royalties on the drug’s US sales, receives a 15% royalty on annual US net sales of vorasidenib up to $1bn.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close